Beta Bionics Reports Preliminary Fourth Quarter 2025 Financial Results
Beta Bionics, Inc. (Nasdaq: BBNX), a leader in diabetes management solutions, has announced its preliminary, unaudited financial results for the fourth quarter ended December 31, 2025. The company reported significant growth in revenue, driven by increased sales across its channels. Furthermore, members of Beta Bionics' management team will be available for in-person meetings in San Francisco, California from January 12-14, 2026, to discuss these results in detail.
Key Financial Metrics for Q4 2025
Beta Bionics expects notable improvements in its financial performance compared to the same quarter last year. The preliminary results are as follows:
- Net Sales: Estimated at least $32.0 million, reflecting an increase of at least 56% from $20.4 million in Q4 2024.
- Durable Medical Equipment (DME) Channel: Projected sales of $22.3 million, up at least 23% compared to $18.1 million in Q4 2024.
- Pharmacy Benefit Plan (PBP) Channel: Expected net sales of $9.7 million, up a remarkable 308% from $2.4 million in Q4 2024.
- Installed Customer Base: Anticipated to reach 35,000 users, which represents a 128% increase from 15,298 users in Q4 2024.
- New Patient Starts: Expected to be 5,581, a growth of at least 36% compared to the 4,084 new patient starts recorded in Q4 2024.
- New Patient Demographics: Approximately 69% of new patient starts are expected to transition from multiple daily injections (MDI), while around 25-30% are anticipated to be individuals with type 2 diabetes.
- Reimbursement through PBP: A low-30s percentage of new patient starts are expected to be reimbursed through the PBP channel, marking an upward trend from the previous quarter.
Upcoming Financial Conference Call
Beta Bionics plans to officially report its comprehensive financial results for both the fourth quarter and the full year 2025 on February 17, 2026, after market close. A conference call, along with a concurrent webcast, is scheduled for that day at 4:30 PM Eastern Time (1:30 PM Pacific Time) to provide insights into the company’s financial performance.
About Beta Bionics
Beta Bionics, Inc. specializes in the design and commercialization of innovative medical devices aimed at enhancing the quality of life for individuals with diabetes. The company's flagship product, the iLet Bionic Pancreas, is the first FDA-cleared insulin delivery device capable of autonomously determining insulin doses, offering significant potential for improved health outcomes among patients requiring insulin therapy.
Important Disclaimers
The preliminary financial results shared in this announcement are unaudited and subject to adjustments as part of Beta Bionics' end-of-period reporting processes. As highlighted, actual financial results for the quarter ended December 31, 2025 may differ materially from these preliminary estimates.
Forward-Looking Statements
This press release may contain forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may result in actual outcomes differing from those projected. Investors are encouraged to review Beta Bionics’ filings with the Securities and Exchange Commission for a comprehensive understanding of potential risks.